Send to

Choose Destination
BJU Int. 2018 Jul;122(1):40-49. doi: 10.1111/bju.14049. Epub 2017 Nov 15.

Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Author information

CamPARI Clinic, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Australian Urology Associates and Department of Surgery, Central Clinical School, Monash University, Melbourne, Vic., Australia.
Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Healthcare Imaging and Monash University, Melbourne, Vic., Australia.
Department of Pathology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Institute of Medical Statistics, Informatics and Epidemiology, University Hospital Cologne, Cologne, Germany.
Department of Urology, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.



To analyse the detection rates of primary magnetic resonance imaging (MRI)-fusion transperineal prostate biopsy using combined targeted and systematic core distribution in three tertiary referral centres.


In this multicentre, prospective outcome study, 807 consecutive biopsy-naïve patients underwent MRI-guided transperineal prostate biopsy, as the first diagnostic intervention, between 10/2012 and 05/2016. MRI was reported following the Prostate Imaging-Reporting and Data System (PI-RADS) criteria. In all, 236 patients had 18-24 systematic transperineal biopsies only, and 571 patients underwent additional targeted biopsies either by MRI-fusion or cognitive targeting if PI-RADS ≥3 lesions were present. Detection rates for any and Gleason score 7-10 cancer in targeted and overall biopsy were calculated and predictive values were calculated for different PI-RADS and PSA density (PSAD) groups.


Cancer was detected in 68% of the patients (546/807) and Gleason score 7-10 cancer in 49% (392/807). The negative predictive value of 236 PI-RADS 1-2 MRI in combination with PSAD of <0.1 ng/mL/mL for Gleason score 7-10 was 0.91 (95% confidence interval ± 0.07, 8% of study population). In 418 patients with PI-RADS 4-5 lesions using targeted plus systematic biopsies, the cancer detection rate of Gleason score 7-10 was significantly higher at 71% vs 59% and 61% with either approach alone (P < 0.001). For 153 PI-RADS 3 lesions, the detection rate was 31% with no significant difference to systematic biopsies with 27% (P > 0.05). Limitations include variability of multiparametric MRI (mpMRI) reading and Gleason grading.


MRI-based transperineal biopsy performed at high-volume tertiary care centres with a significant experience of prostate mpMRI and image-guided targeted biopsies yielded high detection rates of Gleason score 7-10 cancer. Prostate biopsies may not be needed for men with low PSAD and an unsuspicious MRI. In patients with high probability lesions, combined targeted and systematic biopsies are recommended.


#PCSM, #ProstateCancer; MRI-TRUS fusion; cognitive fusion; magnetic resonance imaging; prostate biopsy; transperineal

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center